GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Are Adult Stem Cells?

Adult stem cells are tissue-specific cells that can make more of themselves and produce specialized cells used to maintain and repair particular tissues. Blood-forming stem cells, for example, replenish blood cells rather than make every type of cell in the body. Their range is normally narrower than that of embryonic or induced pluripotent stem cells Stc basics.

What “adult” means

Adult stem cells are also called somatic or tissue-specific stem cells. Despite the name, they are found in children and newborns as well as adults. “Adult” distinguishes this category from embryonic stem cells; it does not describe a minimum donor age Basics.

What Are Adult Stem Cells?

Two properties matter: self-renewal, meaning production of more stem cells, and differentiation, meaning production of specialized cells. Many adult stem cells are multipotent: they generate several related cell types within a tissue. This is different from pluripotency, the ability to generate all the cell types of the adult body Stc basics.

Where adult stem cells are found

Different tissues contain different stem-cell populations. Their everyday role is cell replacement; finding stem cells in a tissue does not establish that collecting and injecting them will repair another organ Stc basics.

Examples of tissue-specific stem cells
Location Population Normal role
Bone marrow; also collected from circulating blood or cord blood Hematopoietic, or blood-forming, stem cells Produce the cells that develop into red blood cells, white blood cells, and platelets Stem cell transplant
Skin Epidermal stem cells Replace cells in the skin’s outer layer Stc basics
Intestinal lining Intestinal stem cells Renew the lining of the gut Stc basics
Limbus, the border of the cornea Limbal stem cells Replenish the corneal surface Holoclar

Cord blood contains blood-forming stem cells, not embryonic stem cells. It is a transplant source, not evidence that all products made from umbilical tissue have the same properties or uses BasicsStem cell transplant.

Adult, embryonic, and iPS cells

Cell source and developmental potential are different questions
Category Source Developmental potential
Adult or tissue-specific stem cells Developed tissues, such as marrow, skin, and intestine Normally limited to related cell types Stc basics
Embryonic stem cells Early embryo Pluripotent Stc basics
Induced pluripotent stem cells, or iPSCs Specialized cells reprogrammed in the laboratory Pluripotent after reprogramming; not the same as an unchanged adult stem-cell preparation Stc basics

Autologous and allogeneic answer a separate question: whether cells come from the patient or a donor. Blood stem-cell transplants can use either source; this classification does not tell you whether the cells are pluripotent Stem cell transplant.

Blood stem-cell transplantation

Blood stem-cell transplantation is an established use for selected blood cancers and disorders, including leukemia, lymphoma, multiple myeloma, aplastic anemia, and sickle cell disease. Transplanted cells are delivered through a vein and restore blood formation after intensive treatment. In some donor transplants, donor immune cells also help attack remaining cancer cells Stem cell transplant.

The infusion itself usually takes 1–5 hours, but recovery is much longer. NCI describes immune recovery as several months after an autologous transplant and about 1–2 years after an allogeneic transplant. Risks include infection, bleeding, infertility, and organ damage associated with the transplant process. Donor transplantation also carries a risk of graft-versus-host disease, in which donor immune cells attack the recipient’s tissues Stem cell transplant.

What MSCs are

Mesenchymal stromal cells, or MSCs, are often marketed as “adult stem cells,” but the terms are not interchangeable. The widely used 2006 laboratory criteria describe cells that adhere to plastic, have a defined surface-marker profile, and can differentiate into bone, fat, and cartilage lineages under laboratory conditions. These criteria identify a cultured cell population; they do not prove that an injection regenerates those tissues in a person 16923606.

An international position statement recommends naming the tissue source and using “stromal” unless stem-cell properties are rigorously demonstrated. Marrow-derived, fat-derived, and cord-derived preparations should not be treated as interchangeable simply because all are called MSCs 31526643.

Ryoncil is one specific approved MSC product. On December 18, 2024, the US FDA approved this donor bone-marrow-derived therapy for steroid-refractory acute graft-versus-host disease in children aged 2 months and older. It is administered by intravenous infusion. The supporting single-arm study enrolled 54 children after allogeneic blood stem-cell transplantation; overall response at day 28 was 70%, including complete and partial responses. There was no concurrent control group, and this response measure is not a cure rate or a measure of organ regrowth Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric.

The FDA summary also reports infections, fever, bleeding, and other adverse reactions. Its findings concern this product and this patient group, not every MSC preparation or diagnosis Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric.

Corneal and skin treatments

Some treatments use tissue-specific cells to replace a damaged surface. In the European Union, Holoclar is authorized for adults with moderate to severe limbal stem-cell deficiency caused by eye burns. A 1–2 mm² sample of the patient’s healthy limbal tissue is grown into a cell-containing sheet and surgically implanted onto the eye. It is not a general treatment for blindness or an intravenous infusion. Reported adverse effects include eye pain and corneal epithelial defects Holoclar.

Japan’s published approval list includes Nepic, a corneal-limbus-derived epithelial sheet for limbal stem-cell deficiency, and Ocural, an oral-mucosa-derived epithelial sheet used to repair the corneal surface in that condition. They use different starting tissues. The list also records JACE, an autologous epidermal sheet with an indication for severe extensive burns under specified conditions. These are examples of named products, not approval of every clinic procedure using similar cells 000283257.pdf.

Approval, research, and clinic services

Established transplantation, an approved manufactured product, an experimental intervention, and a private-clinic service are not the same category. An experimental intervention may be studied in a clinical trial. A product’s approval must be checked against its specific indication and jurisdiction, rather than inferred from the phrase “stem-cell therapy” Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric0003.

Japan has separate frameworks for provision of regenerative medicine under the Act on the Safety of Regenerative Medicine and commercialization of regenerative medical products under the PMD Act. A provision plan is not a product marketing approval and should not be presented as proof of efficacy. The distinction matters when comparing the different interventions discussed in the regenerative medicine overview 0003.

Limits and risks

“From your own body” does not mean risk-free. Collection and administration can cause adverse reactions, and processing can introduce contamination. FDA safety information describes reports of blindness, tumor formation, serious infections, and unwanted immune or inflammatory responses after unapproved regenerative products. These reports identify possible harms; they do not provide a reliable overall complication rate for all adult stem-cell treatments Important patient and consumer information about regenerative medicine therapies.

Risk depends on the product, cell source, processing, delivery route, and patient. The safety discussion for stem-cell therapy in Japan separates these questions rather than treating all cell procedures as one intervention.

  • A cell count is not a stem-cell identity test. Ask how the cells were identified and characterized, not just how many were collected. MSC laboratory criteria describe specific properties, not a total-cell-count threshold 16923606.
  • Laboratory differentiation is not clinical repair. Making a cartilage lineage in culture does not establish that a particular injection restores a damaged joint. Clinical claims need human evidence for the actual product and condition 16923606Stc basics.
  • A listing is not proof of benefit. FDA explicitly warns that a ClinicalTrials.gov listing or a firm’s FDA registration does not establish that a product is legally marketed. Neither should be treated as an efficacy result Important patient and consumer information about regenerative medicine therapies.

Reading a treatment claim

Consider a claim that an “approved MSC infusion” will regrow knee cartilage. Ryoncil’s FDA approval provides a concrete comparison: its source is donor marrow, its route is intravenous, its indication is pediatric steroid-refractory acute graft-versus-host disease, and its measured outcome is response at day 28. None of those details establishes knee-cartilage regeneration. This is a comparison of public documents, not a patient case or a claim of clinical experience Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric.

For an actual offer, ask for:

  1. The exact product name, tissue source, and delivery route.
  2. The applicable product approval, clinical-trial identifier, or Japanese provision-plan number—and which category it represents.
  3. Human results for the same diagnosis: patient numbers, comparison group, outcome measured, and length of follow-up.
  4. Known harms, follow-up arrangements, and established treatments that could be delayed.

Whether a person is eligible is a separate medical question. Diagnosis, current health, and treatment-specific exclusions must be reviewed together, as reflected in the indications and contraindications guide.

Have a question about a proposed cell treatment? Include its name, cell source, and delivery route in your inquiry. An inquiry does not establish eligibility or expected benefit.

Ask a treatment question

The bottom line: Adult stem cells are tissue-specific cells with self-renewal and specialized cell-producing abilities. Their normal role in tissue maintenance is not a promise that an injection can rebuild any organ. Judge a proposed treatment by its exact cells, indication, delivery method, and human evidence—not by the stem-cell label alone Stc basicsImportant patient and consumer information about regenerative medicine therapies.

This information is educational and is not a diagnosis or treatment recommendation. Discuss care decisions with a licensed physician who has reviewed your medical records.